Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.6M
10M shares
52-week range
$0.24 – $2.89
1% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
P/S (TTM)
0.2
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
www.nexgel.comNo one on the platform currently holds NXGL.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 50,960 | $32.3K |
No one on the platform has traded NXGL yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 31.5% | 76.1% | ||||
| Profit Margin % | -26.3% | -130.2% | -147.1% | |||
| Free Cash Flow Margin % | -12.1% | -100.7% | -124.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $16M | +33.1% | $-0.94 | $-0.94–$-0.94 | — | 1 |
| 2027 | $24M | +53.7% | $-0.22 | $-0.22–$-0.22 | — | 1 |
| 2028 | $26M | +7.6% | $-0.05 | $-0.05–$-0.05 | — | 1 |
| 2029 | $28M | +7.9% | $0.35 | $0.35–$0.35 | 0.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-14 | $-0.12 | $-0.40 | -233.3% |
| 2026-05-13 | $-0.07 | $-0.11 | -57.1% |
| 2026-03-31 | $-0.09 | $-0.11 | -22.2% |
| 2025-11-11 | $-0.09 | $-0.08 | +11.1% |
| 2025-08-12 | $-0.01 | $-0.09 | -800.0% |
| 2025-05-13 | $-0.10 | $-0.09 | +10.0% |
| 2025-03-24 | $-0.13 | $-0.08 | +38.5% |
| 2024-11-13 | $-0.10 |
| $-0.11 |
| -10.0% |
| $36M |
| — |
| IINNInspira Technologies OXY B.H.N. Ltd. | $1.05 | -0.94% | $25M | — |
| MLSSMilestone Scientific Inc. | $0.41 | -3.96% | $36M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$NXGL I think we've been under a dollar for around 6 months now. Shouldn't we get notice of an extension any day? With no RS authorization, they must get an extension or face delisting. I dont like all the silence here...
View on StockTwits ↗
$NXGL NEXGEL Announces Date for Investor Update Call https://ir.nexgel.com/news-events/press-releases/detail/128/nexgel-announces-date-for-investor-update-call
View on StockTwits ↗
$NXGL Sequence LifeScience™ Names BIONX Surgical Exclusive U.S. Distributor for Eye Health Portfolio https://www.reddit.com/r/NXGL/s/tceU5Wu9Gr
View on StockTwits ↗
$NXGL To clarify the S-1 Pt. 3 6️⃣ NXGL still has major catalysts ahead. Strategic alternatives update expected in 30–45 days SilverSeal hospital launch (with reimbursement codes) BioNX Surgical backlog clearance Regenerative eye & aesthetics platform rollout Analyst PT: $2.00 7️⃣ Bottom line: The S‑1 is not new dilution, not toxic, and not a death spiral. It’s a standard resale registration for shares already owed from past deals. Bears are using it for FUD because they know NXGL has real catalysts coming. Do your own DD — but don’t let misinformation drive your decisions.
View on StockTwits ↗$NXGL To clarify the S-1 Pt. 2 4️⃣ NXGL shareholders blocked dilution AND blocked a reverse split. In June, shareholders rejected: increasing authorized shares from 25M → 100M any reverse split (1‑for‑2 to 1‑for‑10) NXGL cannot dilute at will. This is one of the cleanest micro‑cap floats on Nasdaq. 5️⃣ This S‑1 is normal housekeeping before strategic alternatives. NXGL formed a Strategic Alternatives & Value Creation Committee on Aug 20. Companies often clean up old financing obligations before announcing: a sale a merger an asset divestiture a recapitalization a strategic partnership This S‑1 is part of that process — not a red flag.
View on StockTwits ↗$NXGL to clarify the S-1 - Pt. 1 Use this exactly as‑is: $NXGL — Important Facts About the S‑1 (Ignore the FUD) A lot of bears are trying to spin the new Form S‑1 into fear, so here are the actual facts: 1️⃣ NXGL is NOT issuing new shares. The 15,252,337 shares in the S‑1 are NOT new dilution. They come from old convertible notes from April & May 2026 and the Celularity transaction. These shares already existed economically — the S‑1 just makes them legally sellable. 2️⃣ No warrants are included. This is huge. Most micro‑cap S‑1s include toxic warrant stacks. NXGL’s does not. This is a resale registration, not a toxic financing. 3️⃣ The S‑1 does NOT increase the float today. The float only increases if noteholders: convert their notes sell the shares The S‑1 does not force conversion and does not force selling. :
View on StockTwits ↗
$NXGL loaded some here. Still holding on to my $LUCY shares and $MGX after selling $MRNA last week
View on StockTwits ↗
$NXGL Really interesting today...Brian getting some of his rich buddies to get in?
View on StockTwits ↗$NXGL Volume of 11M+ premarket. What the hell is this???
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.